During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
|Videos|November 29, 2018
Unresectable HCC with Extrahepatic Involvement
Unresectable HCC with Extrahepatic Involvement
Advertisement
A 77-Year-Old Male With Unresectable HCC and Extrahepatic Involvement
- History and physical exam
- An otherwise healthy, 77-year-old Caucasian male with a history of alcohol use
- Presented to his PCP complaining of abdominal pain, fatigue and an unexplained 10-lb weight loss
- Currently consumes 3-4 alcoholic drinks per day
- ECOG PS 0
- Imaging
- CT scan: 4.5-cm hepatic lesion with arterial hypervascularity, portal venous washout, and a pseudocapsule indicative of hepatocellular carcinoma; no evidence of vascular invasion
- Bone scan: left-sided iliac mass (3.1 cm)
- Chest CT: clear
- Diagnosis: unresectable HCC with extrahepatic involvement
- BCLC stage C
- Child-Pugh A
- AFP Level: 3548.4 ng/mL
- Weight: 72 kg
- Lenvatinib 12 mg QD was initiated.
- He experienced modest weight loss and reported loss of appetite for which he was referred for nutritional therapy
- Imaging at 16 weeks: partial response (0.5 cm)
- 8 months after initiation of therapy: treatment discontinued due to disease progression
Advertisement
Related to this article
The FDA granted RMAT and fast track designations to prizloncabtagene autoleucel , a CD20/CD19 bispecific CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.
Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.
NCCN prostate cancer guidelines now list the ArteraAI Prostate Test (Post-RP), an AI tool that stratifies metastasis risk in biochemical recurrence after prostatectomy.
Eftilagimod alfa plus pembrolizumab and radiotherapy yielded 81.1% disease-free survival at 12 months in patients with resectable soft tissue sarcoma.
Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.
During a live event, Theresa Medina, MD, and participants discussed how disease site, BRAF status, and prior therapy guide treatment selection in metastatic melanoma.
The FDA has approved the PCR-based OncoMate MSI Dx Analysis System as a companion diagnostic to identify MSI-H solid tumors for treatment with pembrolizumab.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
2
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
3
DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC
4
How Patient Factors Steer Treatment Selection in Metastatic Melanoma
5